检查点抑制剂-TKI 联合治疗在肾细胞癌中有效。
Checkpoint Inhibitor-TKI Combos Effective in RCC.
出版信息
Cancer Discov. 2019 Apr;9(4):460. doi: 10.1158/2159-8290.CD-NB2019-024. Epub 2019 Feb 20.
Abstract
Pembrolizumab or avelumab plus axitinib may be effective first-line treatments for clear-cell advanced renal cell carcinoma. In a pair of phase III trials, the checkpoint inhibitor-tyrosine kinase inhibitor combinations extended progression-free survival compared with sunitinib and were associated with relatively manageable side effects.
摘要
派姆单抗或avelumab 联合阿昔替尼可能是透明细胞晚期肾细胞癌的有效一线治疗方法。在两项 III 期临床试验中，与舒尼替尼相比，检查点抑制剂-酪氨酸激酶抑制剂联合治疗延长了无进展生存期，并且副作用相对容易控制。
Zotero 插件